Required Data Elements for Paternity Establishment Affidavits. No changes are proposed to the data elements, but burden has been adjusted to reflect improved automation for processes.

DATES: Comments due September 22, 2026.

ADDRESSES: In compliance with the requirements of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above. You can obtain copies of the proposed collection of information and submit comments by emailing *infocollection@acf.hhs.gov.* Identify all requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: Section 466(a)(5)(C) of the Social Security Act requires states to enact laws ensuring a simple civil process for voluntarily acknowledging paternity via an affidavit. The development and use of an affidavit for the voluntary acknowledgment of paternity would include the minimum requirements of the affidavit specified by the Secretary under section 452(a)(7) of the Social Security Act and give full faith and credit to such an affidavit signed in any other state according to its procedures. The state must provide that, before a mother and putative father can sign a voluntary acknowledgment of paternity, the mother and putative father must be given notice, orally, or through the use of video equipment, and in writing, of the alternatives to, the legal consequences of, and the rights (including any rights, if one parent is a minor, due to minority status) and responsibilities of acknowledging paternity. The affidavits will be used by hospitals, birth record agencies, and other entities participating in the voluntary paternity establishment program to collect information from the parents of nonmarital children.

Respondents: The parents of nonmarital children, state and tribal agencies operating child support programs under Title IV–D of the Social Security Act, hospitals, birth record agencies, and other entities participating in the voluntary paternity establishment program.

Annual Burden Estimates: Annual burden estimates have been updated to remove ordering brochures from the annual burden hours calculation, as ordering brochures is not required under federal guidelines. With advancements in automation and digital service delivery, most partners now rely on electronic devices located in hospitals and other automated public facing platforms to deliver education on paternity establishment and highlight the benefits of signing the paternity establishment affidavit. This results in a 40 percent overall decrease in estimated annual burden compared to the most recently approved annual burden estimates (2024). The number of responses and estimated time per response for the remaining instruments have not changed.

Instrument	Total number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
Training	135,155	1	1	135,155
Paternity Acknowledgment Process	1,372,816	1	0.17	233,379
Data Elements	54	1	1	54
Estimated Total Annual Burden Hours:				368,588

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: 42 U.S.C. 666(a)(5)(C) and 652(a)(7).

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2026–15044 Filed 7–23–26; 8:45 am]

BILLING CODE 4184–41–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–7231]

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). This meeting was announced in the **Federal Register** on June 30, 2026. The amendment is being made to reflect a change in the **DATES**, **ADDRESSES**, and **SUPPLEMENTARY INFORMATION**: *Procedure* portion of the document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Cicely Reese; Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993–0002, 301–796–9025, email: *CBERCTGTAC@fda.hhs.gov,* or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 30, 2026, meeting notice and citation, 91 FR 42203, FDA announced that a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee would be held on July 30, 2026. On page 42203, in the second column, the **DATES** portion of the document is changed to read as follows:

The meeting will be held on July 30, 2026, from 9:30 a.m. to 4:30 p.m. Eastern Time. Online public viewing will be available at the following link on the day of the meeting at: *https://youtube.com/live/7x4xuKJti1o?feature=share.*

On page 42203, in the second column, the **ADDRESSES** portion of the document is changed to read as follows: The meeting will be held at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993–0002. The public will also have the option to participate, and the advisory committee meeting will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On page 42204, in the second column, the **SUPPLEMENTARY INFORMATION**: *Procedure* portion of the document is changed to read as follows: Oral presentations from the public will be scheduled between approximately 12:35 p.m. and 2:05 p.m. Eastern Time.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*) and 21 CFR part 14, relating to the advisory committees.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–15017 Filed 7–23–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–6771]

Cellular, Tissue, and Gene Therapies Advisory Committee; Amendment of Notice—Biologics License Application (BLA) 125842 From Capricor, Inc. for Deramiocel (Human Allogeneic Cardiosphere-Derived Cells)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee (the Committee). This meeting was announced in the **Federal Register** on June 29, 2026. The amendment is being made to reflect a change in the **DATES**, **ADDRESSES**, and **SUPPLEMENTARY INFORMATION**: *Procedure* portion of the document. There are no other changes.

FOR FURTHER INFORMATION CONTACT: Cicely Reese; Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 1, Rm. 3215, Silver Spring, MD 20993–0002, 301–796–9025, email: *CBERCTGTAC@fda.hhs.gov,* or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 29, 2026, meeting notice and citation, 91 FR 39101, FDA announced that a meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee would be held on July 29, 2026. On page 39101, in the third column, the **DATES** portion of the document is changed to read as follows:

The meeting will be held on July 29, 2026, from 9:30 a.m. to 4:50 p.m. Eastern Time. Online public viewing will be available at the following link on the day of the meeting at: *https://youtube.com/live/SUNn6YcBhnw?feature=share.*

On page 39101, in the third column, the **ADDRESSES** portion of the document is changed to read as follows: The meeting will be held at FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993–0002. The public will also have the option to participate, and the advisory committee meeting will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform. On page 39102, in the third column, the **SUPPLEMENTARY INFORMATION**: *Procedure* portion of the document is changed to read as follows: Oral presentations from the public will be scheduled between approximately 12:05 p.m. and 1:35 p.m. Eastern Time.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. 1001 *et seq.*) and 21 CFR part 14, relating to the advisory committees.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–15016 Filed 7–23–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–1199]

Francis Esteban Matos: Final Debarment Order

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring Francis Esteban Matos for a period of 5 years from importing or offering for import any drug into the United States. FDA bases this order on a finding that Mr. Matos was convicted of a felony under Federal law. The factual basis supporting Mr. Matos's conviction, as described below, is conduct relating to the importation into the United States of a drug or controlled substance. Mr. Matos was given notice of the proposed debarment and was given an opportunity to request a hearing to show why he should not be debarred. As of May 18, 2026 (more than 30 days after receipt of the notice), Mr. Matos had not responded. Mr. Matos's failure to respond and request a hearing constitutes a waiver of his right to a hearing concerning this matter.

DATES: This order is applicable July 24, 2026.

ADDRESSES: Any application by Mr. Matos for termination of debarment under section 306(d)(1) of the FD&C Act (21 U.S.C. 335a(d)(1)) may be submitted at any time as follows:

Electronic Submissions

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. An application submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your application will be made public, you are solely responsible for ensuring that your application does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your application, that information will be posted on *https://www.regulations.gov.*
- If you want to submit an application with confidential information that you do not wish to be made available to the public, submit the application as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For a written/paper application submitted to the Dockets Management